Anne Largeot

Luxembourg, LU, Luxembourg

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 21 publications

Increased LEF1 protein levels and isoform switching drive cell proliferation in chronic lymphocytic leukemia.

Increased LEF1 protein levels and isoform switching drive cell proliferation in chronic lymphocytic leukemia.

Journal: Blood

Published: May 28, 2025

Restoring NK Cell Cytotoxicity Post-Cryopreservation via Synthetic Cells.

Restoring NK Cell Cytotoxicity Post-Cryopreservation via Synthetic Cells.

Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)

Published: March 30, 2025

Retinal determination network reactivation drives chemoresistance and blocks myeloid differentiation in acute myeloid leukemia.

Retinal determination network reactivation drives chemoresistance and blocks myeloid differentiation in acute myeloid leukemia.

Journal: Cell reports

Published: March 03, 2025

Assessment of translation rate in leukemic cells and immune cells of the microenvironment by OPP protein synthesis assay.

Assessment of translation rate in leukemic cells and immune cells of the microenvironment by OPP protein synthesis assay.

Journal: Methods in cell biology

Published: October 11, 2024

The small inhibitor WM-1119 effectively targets KAT6A-rearranged AML, but not KMT2A-rearranged AML, despite shared KAT6 genetic dependency.

The small inhibitor WM-1119 effectively targets KAT6A-rearranged AML, but not KMT2A-rearranged AML, despite shared KAT6 genetic dependency.

Journal: Journal of hematology & oncology

Published: May 10, 2024

Protein arginine methyltransferase 2 controls inflammatory signaling in acute myeloid leukemia.

Protein arginine methyltransferase 2 controls inflammatory signaling in acute myeloid leukemia.

Journal: Communications biology

Published: January 19, 2024

Targeting mRNA translation aberrations: A novel approach for therapy in chronic lymphocytic leukemia.

Targeting mRNA translation aberrations: A novel approach for therapy in chronic lymphocytic leukemia.

Journal: Cancer communications (London, England)

Published: July 18, 2023

Interleukin-27 potentiates CD8+ T-cell-mediated antitumor immunity in chronic lymphocytic leukemia.

Interleukin-27 potentiates CD8+ T-cell-mediated antitumor immunity in chronic lymphocytic leukemia.

Journal: Haematologica

Published: November 22, 2022

Inhibition of MYC translation through targeting of the newly identified PHB-eIF4F complex as a therapeutic strategy in CLL.

Inhibition of MYC translation through targeting of the newly identified PHB-eIF4F complex as a therapeutic strategy in CLL.

Journal: Blood

Published: July 18, 2022

Extracellular Vesicle Secretion by Leukemia Cells In Vivo Promotes CLL Progression by Hampering Antitumor T-cell Responses.

Extracellular Vesicle Secretion by Leukemia Cells In Vivo Promotes CLL Progression by Hampering Antitumor T-cell Responses.

Journal: Blood cancer discovery

Published: February 24, 2022

The Tumor Microenvironment-Dependent Transcription Factors AHR and HIF-1α Are Dispensable for Leukemogenesis in the Eµ-TCL1 Mouse Model of Chronic Lymphocytic Leukemia.

The Tumor Microenvironment-Dependent Transcription Factors AHR and HIF-1α Are Dispensable for Leukemogenesis in the Eµ-TCL1 Mouse Model of Chronic Lymphocytic Leukemia.

Journal: Cancers

Published: August 20, 2021

Intrinsic Resistance of Chronic Lymphocytic Leukemia Cells to NK Cell-Mediated Lysis Can Be Overcome In Vitro by Pharmacological Inhibition of Cdc42-Induced Actin Cytoskeleton Remodeling.

Intrinsic Resistance of Chronic Lymphocytic Leukemia Cells to NK Cell-Mediated Lysis Can Be Overcome In Vitro by Pharmacological Inhibition of Cdc42-Induced Actin Cytoskeleton Remodeling.

Journal: Frontiers in immunology

Published: October 19, 2020

Showing 1-12 of 21

Last Updated: 09/26/2026